Michihata, Nobuaki
Suzuki, Takanori http://orcid.org/0000-0002-8940-2393
Yoshikawa, Tetsushi
Saito, Kazuyoshi
Matsui, Hiroki
Fushimi, Kiyohide
Yasunaga, Hideo
Funding for this research was provided by:
Ministry of Health, Labour and Welfare (21AA2007, 20AA2005)
Ministry of Education, Culture, Sports, Science and Technology, Japan (20H03907)
Article History
Received: 21 February 2022
Revised: 5 July 2022
Accepted: 10 July 2022
First Online: 4 August 2022
Declarations
:
: All authors have no potential conflicts of interest to disclose.
: The present study was approved by the Institutional Review Board of The University of Tokyo (approval number: 3501-(3); 25 December 2017).
: The requirement for informed consents was waived because of the anonymous nature of the data.
: This paper isn’t included an individual’s data or image.
: We do not want open access.
: This study showed by restricted cubic spline that the dose of intravenous immunoglobulin for Kawasaki disease in acute phase was 2g/kg.